Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shares rose 6.5% during trading on Monday . The company traded as high as $19.63 and last traded at $19.62, with a volume of 401,043 shares traded. The stock had previously closed at $18.43.

AERI has been the subject of a number of recent research reports. Zacks Investment Research lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 19th. Brean Capital restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, May 3rd. Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, May 3rd. Finally, Cantor Fitzgerald initiated coverage on Aerie Pharmaceuticals in a research note on Thursday, June 2nd. They issued a “buy” rating and a $44.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $42.50.

The company’s market capitalization is $527.16 million. The stock has a 50-day moving average of $17.81 and a 200-day moving average of $16.01.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.02. Equities research analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.74) EPS for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of Aerie Pharmaceuticals stock in a transaction dated Friday, July 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.